Fig. 4From: Soluble factors in COVID-19 mRNA vaccine-induced myocarditis causes cardiomyoblast hypertrophy and cell injury: a case reportCellular viability of sera-treated groups. Cells were seed in DMEM supplemented with 10% FBS, after 24 h medium was changed to 1% FBS, and 5% of plasma was added from a healthy human control or myocarditis patient (during acute and recovery phases) for 48 h. Cell viability was determined by an Alamar blue assay. For statistical analysis, an ANOVA was calculated considering p < 0.01 **Back to article page